Avantor, Inc. Restructuring and Related Cost, Cost Incurred to Date
Avantor, Inc. (AVTR) had Restructuring and Related Cost, Cost Incurred to Date of $82.80 million as of 2025-09-30, per its 10-Q filed 2025-10-29.
Financial Statements › Notes › Restructuring and Related Activities › Restructuring and Related Cost, Expected Cost
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2025-10-29
- 2025-09-30: Restructuring and Related Cost, Cost Incurred to Date $82.80M.
- 2022-12-31: Restructuring and Related Cost, Cost Incurred to Date $9.60M.
- 2021-12-31: Restructuring and Related Cost, Cost Incurred to Date $9.60M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2025-09-30 | $82.80M 10-Q · filed 2025-10-29 |
| 2022-12-31 | $9.60M 10-K · filed 2023-02-14 |
| 2021-12-31 | $9.60M 10-K · filed 2022-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRUKER CORP (BRKR) | United States | $9.706B | -128.75 |
| REVVITY, INC. (RVTY) | United States | $16.814B | 53.44 |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |